SoftBank will also be investing large amounts into the company where each will hold 50% equal stakes. Tempus will also be leveraging its expertise in genomic testing and real world data analytics to aid in building clinical sequencing capabailits, aggregate medical data and also develop AI models that will be tailored for Japanese patients. The ultimate goal is to offer AI- powered insights to hospitals, which will go a long way to help doctors determine the most effective, personalized treatments for patients.
In the course of the Joint Venture SB Tempus will be offering three core services to hospitals, beginning with operations in August 2025. Currently,only about 1% of Japanese patients will be undegroing genomic testingas compared to approximately 30% in the US. The venture also aims to bridge the gap by explanding access and usage. This will be going beyond cancer care, SB Tempus is also thinking about going into areas such as neuropsychology, radiology and cardiology.
The move is part of Son's broader push into artificial intelligence which he envisions will be 10,000 times much more smarter than humans within a decade.
In conclusion, it strategically signals SoftBank's transition from a defensive investment in regard to its lossed with its Vision Fund, to a much renewed focus on AI driven growth initiatives.